GB0006537D0 - Assays and screening methods - Google Patents

Assays and screening methods

Info

Publication number
GB0006537D0
GB0006537D0 GBGB0006537.5A GB0006537A GB0006537D0 GB 0006537 D0 GB0006537 D0 GB 0006537D0 GB 0006537 A GB0006537 A GB 0006537A GB 0006537 D0 GB0006537 D0 GB 0006537D0
Authority
GB
United Kingdom
Prior art keywords
assays
screening methods
hcv
renatured
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0006537.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB0006537.5A priority Critical patent/GB0006537D0/en
Publication of GB0006537D0 publication Critical patent/GB0006537D0/en
Priority to DE60116474T priority patent/DE60116474T2/de
Priority to US10/221,943 priority patent/US7078215B2/en
Priority to AU42694/01A priority patent/AU4269401A/en
Priority to PCT/IB2001/000527 priority patent/WO2001068818A2/en
Priority to EP01915613A priority patent/EP1278867B1/en
Priority to JP2001567302A priority patent/JP2003526361A/ja
Priority to ES01915613T priority patent/ES2254380T3/es
Priority to CA002403405A priority patent/CA2403405A1/en
Priority to AT01915613T priority patent/ATE315093T1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Hydrogenated Pyridines (AREA)
  • Detergent Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB0006537.5A 2000-03-17 2000-03-17 Assays and screening methods Ceased GB0006537D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0006537.5A GB0006537D0 (en) 2000-03-17 2000-03-17 Assays and screening methods
AT01915613T ATE315093T1 (de) 2000-03-17 2001-03-14 Hcv ns2/3 fragmente und ihre verwendungen
PCT/IB2001/000527 WO2001068818A2 (en) 2000-03-17 2001-03-14 Hcv ns2/3 fragments and uses thereof
US10/221,943 US7078215B2 (en) 2000-03-17 2001-03-14 HCV NS2/3 fragments and uses thereof
AU42694/01A AU4269401A (en) 2000-03-17 2001-03-14 HCV NS2/3 fragments and uses thereof
DE60116474T DE60116474T2 (de) 2000-03-17 2001-03-14 Hcv ns2/3 fragmente und ihre verwendungen
EP01915613A EP1278867B1 (en) 2000-03-17 2001-03-14 Hcv ns2/3 fragments and uses thereof
JP2001567302A JP2003526361A (ja) 2000-03-17 2001-03-14 Ｈｃｖｎｓ２／３フラグメント及びその使用
ES01915613T ES2254380T3 (es) 2000-03-17 2001-03-14 Fragmentos de ns2/3 del vhc y usos de los mismos.
CA002403405A CA2403405A1 (en) 2000-03-17 2001-03-14 Hcv ns2/3 fragments and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0006537.5A GB0006537D0 (en) 2000-03-17 2000-03-17 Assays and screening methods

Publications (1)

Publication Number Publication Date
GB0006537D0 true GB0006537D0 (en) 2000-05-10

Family

ID=9887885

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0006537.5A Ceased GB0006537D0 (en) 2000-03-17 2000-03-17 Assays and screening methods

Country Status (10)

Country Link
US (1) US7078215B2 (enExample)
EP (1) EP1278867B1 (enExample)
JP (1) JP2003526361A (enExample)
AT (1) ATE315093T1 (enExample)
AU (1) AU4269401A (enExample)
CA (1) CA2403405A1 (enExample)
DE (1) DE60116474T2 (enExample)
ES (1) ES2254380T3 (enExample)
GB (1) GB0006537D0 (enExample)
WO (1) WO2001068818A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3878132B2 (ja) 2000-12-15 2007-02-07 ベーリンガー インゲルハイム （カナダ） リミテッド 精製活性型ｈｃｖｎｓ２／３プロテアーゼ
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
US20090233266A1 (en) * 2005-03-10 2009-09-17 The Rockefeller University Structure of the hepatitis c virus ns2 protein
ES2386462T3 (es) * 2005-10-28 2012-08-21 Boehringer Ingelheim International Gmbh Ensayo de la actividad NS2/3 del virus de la hepatitis C
EP2388312A1 (en) 2010-05-17 2011-11-23 Curetis AG Universally applicable lysis buffer and processing methods for the lysis of bodily samples

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
IT1277914B1 (it) 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6280940B1 (en) * 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
CA2383411A1 (en) * 1999-08-30 2001-03-08 Paul L. Darke Hepatitis c virus replication inhibitors
JP3878132B2 (ja) * 2000-12-15 2007-02-07 ベーリンガー インゲルハイム （カナダ） リミテッド 精製活性型ｈｃｖｎｓ２／３プロテアーゼ

Also Published As

Publication number Publication date
ATE315093T1 (de) 2006-02-15
US7078215B2 (en) 2006-07-18
WO2001068818A2 (en) 2001-09-20
DE60116474D1 (de) 2006-03-30
DE60116474T2 (de) 2006-09-07
JP2003526361A (ja) 2003-09-09
CA2403405A1 (en) 2001-09-20
US20040054134A1 (en) 2004-03-18
AU4269401A (en) 2001-09-24
ES2254380T3 (es) 2006-06-16
EP1278867B1 (en) 2006-01-04
WO2001068818A3 (en) 2002-03-21
EP1278867A2 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
IT1272179B (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
EP1025204A4 (en) Methods and materials for the growth of primate-derived primordial stem cells
DE60131262D1 (en) Ubiquitin-ligase-assay
AU4965799A (en) Bioreactor and cell culturing processes using the bioreactor
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ATE274588T1 (de) Mutante alpha-amylase mit zusätzlicher disulfidverbindung
IL141308A0 (en) Methods, instruments and materials for chondrocyte cell transplantation
AU2001282908A1 (en) Bioreactor and bioprocessing technique
DK0850307T3 (da) Alkalifile og termofile mikroorganismer og enzymer, der opnås derfra
IL153095A0 (en) Embryonic stem cells, methods for culturing the same and methods utilizing the same
IS5028A (is) Serínpróteasatálmar, einkum við lifrarbólgu C veiru NS3 próteasa
DE69942068D1 (de) Erzeugen eines nichtlinearen modells und erzeugen tzung desselben
WO1999049807A3 (en) A device and method for performing a biological modification of a fluid
DE60010098D1 (de) 28-epirapaloge
DE60009575D1 (de) Nachweis von bakterien und bakteriophagen mit immobilisierten enzymsubstraten
ATE216400T1 (de) Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle
DE69938896D1 (de) Den gasen unter vorbeugung von kapillarer kondensation
ITRM950573A0 (it) Procedimento per produrre - in forma pura ed in quantita' elevate- polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e metodologia per riprodurre e saggiare efficacemente in vitro l'attivi-ta' proteolitica dei suddetti polipeptidi
DE68915112D1 (de) Spiro-isochinolin-pyrrolidin-tetrone und Analoge davon, verwendbar als Aldosereduktase-Inhibitoren.
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
AU4269401A (en) HCV NS2/3 fragments and uses thereof
WO2003033145A1 (fr) Materiau photocatalytique et son utilisation
ATE329015T1 (de) Enzyme mit s-adenosyl-l-homocystein-hydrolase- ähnlicher aktivität.
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
WO2000006750A3 (en) Method for autoactivation of procaspase 8

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)